Digeranyl bisphosphonate

CAS No. 878143-03-4

Digeranyl bisphosphonate( —— )

Catalog No. M33063 CAS No. 878143-03-4

Digeranyl bisphosphonate (DGBP) is a potent geranylgeranyl pyrophosphate (GGPP) synthase inhibitor that impedes the geranyl pyrophosphorylation of Rac1 and induces autophagy without causing apoptosis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 400 Get Quote
5MG 503 Get Quote
10MG 806 Get Quote
25MG 1398 Get Quote
50MG 1822 Get Quote
100MG 2250 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Digeranyl bisphosphonate
  • Note
    Research use only, not for human use.
  • Brief Description
    Digeranyl bisphosphonate (DGBP) is a potent geranylgeranyl pyrophosphate (GGPP) synthase inhibitor that impedes the geranyl pyrophosphorylation of Rac1 and induces autophagy without causing apoptosis.
  • Description
    Digeranyl bisphosphonate (DGBP) is a potent geranylgeranylpyrophosphate (GGPP) synthase inhibitor, which inhibits geranylgeranylation of Rac1.
  • In Vitro
    Digeranyl bisphosphonate (DGBP) impairs geranylgeranylation. To examine if Digeranyl bisphosphonate modulates Rac1 activity, cells are exposed to vehicle or Digeranyl bisphosphonate. Rac1 activation increases significantly after chrysotile exposure, whereas the activity in Digeranyl bisphosphonate -treated cells is reduced to control levels. Digeranyl bisphosphonate also decreases H2O2 generation in chrysotile-exposed macrophages.
  • In Vivo
    To further evaluate the effect of Digeranyl bisphosphonate (DGBP; 0.2 mg/kg/day) in protecting mice from chrysotile-induced pulmonary fibrosis, the mice are administered vehicle or Digeranyl bisphosphonate subcutaneously in osmotic pumps, and exposed to saline or chrysotile the following day. Mice exposed to saline have normal lung architecture with vehicle and Digeranyl bisphosphonate treatment. Chrysotile-exposed mice that receive vehicle have significant architectural changes in their lung parenchyma and large amounts of collagen deposition, whereas the lungs of the Digeranyl bisphosphonate -treated mice are essentially normal. To investigate the effect of Digeranyl bisphosphonate in Bleomycin-induced fibrosis, osmotic pumps containing either vehicle or Digeranyl bisphosphonate are implanted subcutaneously in WT mice. Mice are exposed to saline or Bleomycin the following day. Digeranyl bisphophonate (0.2 mg/kg/day)-treated mice show significantly less hydroxyproline compared to vehicle-treated mice exposed to Bleomycin.
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Rho
  • Recptor
    Rho | Ras
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    878143-03-4
  • Formula Weight
    536.4
  • Molecular Formula
    C21H34Na4O6P2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 2 mg/mL (3.73 mM; Ultrasonic ) H2O : 2 mg/mL (3.73 mM; Ultrasonic)
  • SMILES
    C/C(C)=C\CC/C(C)=C/CC(P([O-])([O-])=O)(P([O-])([O-])=O)C/C=C(C)/CC/C=C(C)\C.[Na+].[Na+].[Na+].[Na+]
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Osborn-Heaford HL, et al. Targeting the isoprenoid pathway to abrogate progression of pulmonary fibrosis. Free Radic Biol Med. 2015 Sep;86:47-56.?
molnova catalog
related products
  • Z62954982

    Z62954982 (ZINC08010136) is a selective inhibitor of Rac1, which stunts the growth and branching of neurons.

  • (E/Z)-ZINC09659342

    (E/Z)-ZINC09659342 is an inhibitor of Lbc-Rho A interaction.

  • CCG-1423

    CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.